Impact of serum-derived bovine immunoglobulin/protein isolate therapy on irritable bowel syndrome and inflammatory bowel disease: a survey of patient perspective

Figures & data

Table 1 Characteristics of survey respondents

Characteristics	Percentage of respondents diagnosed with:
	IBS or IBD (n=595)	IBS (n=344)	IBD (n=251)
Age (years)
<50	24.7	24.1	25.5
50–64	25.8	23.8	35.1
65–75	29.9	29.1	25.9
>75	22.3	21.5	12.4
Not reported	1.7	1.5	1.2
Mean ± SD	59.6±16.46	60.9±16.76	57.7±15.89
Gender
Male	23.2	20.9	26.3
Female	75.3	77.3	72.5
Not reported	1.5	1.7	1.2
Primary diagnosisa	100	57.8	42.2
Duration of diagnosis
<1 year	26.2	29.4	21.9
1–3 years	24.2	25.3	22.7
>3 years	50.1	45.9	55.8

Note:

a Three percent of patients reported both IBS and IBD as primary diagnosis.

Abbreviations: IBS, irritable bowel syndrome; IBD, inflammatory bowel disease; SD, standard deviation.

Table 2 Medications used to manage condition of respondents

Number of medications used since diagnosis	Percentage of respondents diagnosed with
	IBS (n=344)	IBD (n=251)
0	11.9	5.6
1	10.8	7.2
2	16.0	14.7
3	11.9	12.4
4	9.0	12.4
5	8.4	11.6
≥6	11.9	25.1
Not reported	20.1	11.2
Mean ± SD	3.3±3.5	4.8±4.2
Nature of SBI prescription
First time	21.8	25.9
Refill after ≤6 months usage	41.6	40.2
Refill after >6 months usage	36.0	32.3

Abbreviations: IBS, irritable bowel syndrome; IBD, inflammatory bowel disease; SD, standard deviation; SBI, serum-derived bovine immunoglobulin/protein isolate.

Figure 1 Stool frequency reported by IBS and IBD patients before and during SBI therapy.

Notes: Daily stool frequency reported by respondents diagnosed with (A) IBS or (B) IBD, before starting SBI therapy (gray bars) and during SBI therapy (black bars). The dotted line indicates a normal stool frequency defined as ≤4 bowel movements per day. Mean daily stool numbers for IBS patients decreased from 5.7±3.7 per day before SBI to 2.3±1.8 during the use of SBI (P=0.0001). Mean daily stool numbers for IBD patients decreased from 7.4±4.9 stools per day before SBI to 3.0±2.0 following SBI therapy (P=0.0001).
Abbreviations: IBS, irritable bowel syndrome; IBD, inflammatory bowel disease; SBI, serum-derived bovine immunoglobulin/protein isolate.

Figure 2 Patient-reported impact of disease condition on daily life activities.

Note: Patients diagnosed with IBS or IBD who were prescribed SBI responded to survey questions (from Agree Very Strongly to Disagree Very Strongly) about the impact of their disease condition on doing their job or activities they enjoy.
Abbreviations: IBS, irritable bowel syndrome; IBD, inflammatory bowel disease; SBI, serum-derived bovine immunoglobulin/protein isolate.

Figure 3 Patient-reported impact of SBI on return to daily life activities.

Note: Patients diagnosed with IBS or IBD who were prescribed SBI responded to survey questions (from Agree Very Strongly to Disagree Very Strongly) about the impact of SBI on their return to daily activities and overall management of their disease condition.
Abbreviations: IBS, irritable bowel syndrome; IBD, inflammatory bowel disease; SBI, serum-derived bovine immunoglobulin/protein isolate.

Table 3 Matched comparison of aggregated answers to questions regarding the impact of disease condition and SBI on daily life activities among IBS and IBD respondents

Survey question			SBI (EnteraGam^®) has allowed me to get back to doing activities I enjoy			SBI (EnteraGam^®) has helped me manage my condition
My condition prevented me:	Response	N	Agreea	Disagreeb	n/ac	Agreea	Disagreeb	n/ac
From doing things I enjoy	Agree	525	492 (93.7%)	26 (4.9%)	7 (1.3%)	509 (96.9%)	13 (2.5%)	3 (0.6%)
	Disagree	62	38 (61.3%)	16 (25.8%)	8 (12.9%)	49 (79.0%)	10 (16.1%)	3 (4.8%)
	n/a	8	4 (50.0%)	0	4 (50.0%)	4 (50.0%)	0	4 (50.0%)
From doing my job	Agree	345	337 (97.7%)	8 (2.3%)	0	326 (94.5%)	19 (5.5%)	0
	Disagree	156	142 (91.0%)	10 (6.4%)	4 (2.6%)	129 (82.7%)	17 (10.9%)	10 (6.4%)
	n/a	94	83 (88.3%)	5 (5.3%)	6 (6.4%)	79 (84.0%)	6 (6.4%)	9 (9.6%)

Notes:

a Represents the sum of answers from respondents who agreed, agreed strongly, and agreed very strongly.

b Represents the sum of answers from respondents who disagreed, disagreed strongly, and disagreed very strongly.

c No answer provided by respondent. Data presented as n (%).

Abbreviations: IBS, irritable bowel syndrome; IBD, inflammatory bowel disease; n/a, not available; SBI, serum-derived bovine immunoglobulin/protein isolate.